BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla
Ventures Acquisition Co. (Nasdaq: KVSA) ("KVSA"), a special purpose
acquisition company sponsored by an affiliate of Khosla Ventures,
LLC ("Khosla Ventures"), today announced that it will voluntarily
transfer the listing of its Class A common stock, par value
$0.0001 per share ("Class A Common
Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York
Stock Exchange ("NYSE") in connection with, and following the
closing of, the previously announced business combination (the
"Business Combination") with Valo Health, Inc. ("Valo"), the wholly
owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of
Class A Common Stock of the post-Business Combination company, to
be renamed Valo Health Holdings, Inc., will trade under the stock
symbol "VH". KVSA's Class A Common Stock will continue to
trade on Nasdaq until the closing of the Business Combination.
In compliance with Nasdaq's Listing Rules, today KVSA provided
Nasdaq with notice of its intent to delist its Class A Common Stock
from Nasdaq after market close on November
19, 2021. The NYSE listing and Nasdaq delisting are subject
to the closing of the Business Combination and fulfillment of all
NYSE listing requirements.
About Valo Health
Valo Health is a technology company built to transform the
drug discovery and development process using human-centric data and
artificial intelligence driven computation. As a digitally native
company, Valo Health aims to fully integrate
human-centric data across the entire drug development lifecycle
into a single unified architecture, thereby accelerating the
discovery and development of life-changing drugs while
simultaneously reducing the cost, time, and failure rate. The
company's Opal Computational Platform™
consists of an integrated set of capabilities designed to transform
data into valuable insights that may accelerate discoveries and
enable Valo Health to advance a robust pipeline of
programs across cardiovascular metabolic renal, oncology, and
neurodegenerative disease. Founded by Flagship
Pioneering and headquartered in Boston, MA, Valo Health also has
offices in Lexington, MA,
San Francisco, CA, Princeton, NJ, and in Branford, CT. To learn more,
visit www.valohealth.com.
About KVSA
KVSA is a special purpose acquisition company sponsored by
affiliates of Khosla Ventures. Khosla Ventures manages a series of
venture capital funds that make early-stage venture capital
investments and provide strategic advice to entrepreneurs building
companies with lasting significance. The firm was founded in 2004
by Vinod Khosla, co-founder of Sun
Microsystems. Khosla Ventures has over $14 billion dollars of
assets under management and focuses on a broad range of sectors
including artificial intelligence, agriculture/food, consumer,
enterprise, financial services, health, space, sustainable energy,
robotics, VR/AR and 3D printing. Collectively, Khosla Ventures
portfolio of investments has created nearly half a trillion dollars
in market value.
Forward-Looking Statements
This communication contains certain forward-looking statements
within the meaning of the federal securities laws with respect to
the proposed transaction between Valo, Valo Health and KVSA.
These forward-looking statements generally are identified by the
words "believe," "project," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result," and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this communication. You should
carefully consider the risks and uncertainties described in the
"Risk Factors" section of KVSA's Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, the registration statement on Form
S-4, and other documents filed by KVSA from time to time with the
SEC. These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Valo, Valo Health and KVSA assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Neither Valo, Valo Health nor
KVSA gives any assurance that either Valo, Valo Health or KVSA will
achieve its expectations.
Additional Information and Where to Find It /
Non-Solicitation
In connection with the proposed transaction, KVSA has filed, and
the SEC has declared effective, a Registration Statement on Form
S-4 containing a proxy statement/prospectus. The proxy
statement/prospectus was sent to the stockholders of KVSA on
or about October 22, 2021. KVSA also
will file other documents regarding the proposed transaction with
the SEC. Before making any voting decision, investors and security
holders of KVSA are urged to read the proxy statement/prospectus
and all other relevant documents filed or that will be filed with
the SEC in connection with the proposed transaction as they become
available because they will contain important information about the
proposed transaction. Investors and security holders will be able
to obtain free copies of the proxy statement/prospectus and all
other relevant documents filed or that will be filed with the SEC
by KVSA through the website maintained by the SEC at
www.sec.gov.
Participants in Solicitation
KVSA, Valo and Valo Health and their respective directors
and executive officers may be deemed to be participants in the
solicitation of proxies from KVSA's stockholders in connection with
the proposed transaction. Information about persons who may be
deemed participants in the solicitation is set forth in KVSA's
filings with the SEC. To the extent that holdings of KVSA's
securities have changed since the amounts printed in KVSA's
Registration Statement on Form S-1, such changes have been or will
be reflected on Statements of Change in Ownership on Form 4 filed
with the SEC. A list of the names of such directors and executive
officers and information regarding their interests in the business
combination are contained in the proxy statement/prospectus. You
may obtain free copies of these documents as described in the
preceding paragraph.
No Offer or Solicitation
These communications do not constitute an offer to sell or the
solicitation of an offer to buy any securities, or a solicitation
of any vote or approval, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act, or an
exemption therefrom.
View original
content:https://www.prnewswire.com/news-releases/khosla-ventures-acquisition-co-announces-planned-transfer-of-listing-to-nyse-in-connection-with-its-proposed-business-combination-with-valo-health-301411574.html
SOURCE Khosla Ventures Acquisition Co.